All these factors are compounded by the negative phenotype making CD20-negative DLBCL resistant to the otherwise beneficial standard chemotherapeutic regimens [7], posing a therapeutic challenge to the clinician. Here, MS4A1 is linked to diffuse large B-cell lymphoma.